Axumin (fluciclovine F 18) injection has been added to the National Comprehensive Cancer Network® (“NCCN”) Clinical Practice Guidelines in Oncology for Prostate Cancer. These updated NCCN Guidelines state that F-18 fluciclovine PET/CT or PET/MRI should be considered in the clinical workup of patients with recurrence or progression of their prostate cancer. {read more here}